Originator Organization ETH ZürichStartup |
Active Organization ETH ZürichStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CH | ETH ZürichStartup | 01 Nov 2024 |